(1R,2R)-2-苯甲酰基氨基-环己烷羧酸 | 16524-13-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (1R,2R)-2-苯甲酰基氨基-环己烷羧酸
• 英文名称: 2-benzoylamino-cyclohexanecarboxylic acid
• 英文别名: 2-Benzamino-hexahydrobenzoesaeure；N-Benzoyl-hexahydroanthranilsaeure；2-Benzamino-cyclohexan-carbonsaeure-(1)；2-Benzoylamino-cyclohexancarbonsaeure；2-(Benzoylamino)cyclohexanecarboxylic acid；2-benzamidocyclohexane-1-carboxylic acid
• CAS: 16524-13-3
• 化学式: C₁₄H₁₇NO₃
• mdl: MFCD17020879
• 分子量: 247.294
• InChiKey: PUANNVQABXUYKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-甲基哌啶 、 (1R,2R)-2-苯甲酰基氨基-环己烷羧酸 以94的产率得到N-[(1R,2S)-2-(4-methylpiperidine-1-carbonyl)cyclohexyl]benzamide
  参考文献：
  名称：

  Cyclohexylbenzamide derivatives, their preparations and their use as

  摘要：

  化合物公式为：##STR1## 其中R.sub.1代表能够与芳香环环化的烷氧基；R.sub.2、R.sub.3和R.sub.4各自独立地代表氢、卤素或烷氧基、氨基、烷基氨基或烷基-羰基氨基基团，而Z代表不同取代的哌啶基团；以及它们与药用酸的加合物。公式I的化合物是强效的胃肠运动促进剂。

  公开号：

  US05273983A1
• 作为产物：
  描述：

  2-benzamidocyclohexane-1-carboxylic acid;1-phenylpropan-1-amine 、 sodium hydroxide 生成 (1R,2R)-2-苯甲酰基氨基-环己烷羧酸
  参考文献：
  名称：

  NOHIRA, HIROYUKI;NOHIRA, MISAKO;YOSHIDA, SHIN-ICHI;OSADA, AYAKO;TERUNUMA,+, BULL. CHEM. SOC. JAP., 61,(1988) N 4, 1395-1396

  摘要：

  DOI：

文献信息

• [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105802A1

  公开（公告）日：2005-11-10

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，可选地具有取代基的碳氢基团等；R3是未取代的（即缺失），氢原子等；R4和R5相同或不同，每个是氢原子，可选地具有取代基的碳氢基团等；R6是（环状基团，可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个是氢原子，卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；---表示未取代的（即缺失）或单键；---表示单键或双键，或其盐等。
• 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient
  申请人：——

  公开号：US20030166574A1

  公开（公告）日：2003-09-04

  A 1,3,4-oxadiazoline derivative of formula (I) 1 , wherein W is oxygen, sulfer; R is hydrogen, alkyl, CycA, etc.; AA 1 is a single bond, amino acid residue, etc.; AA 2 is a single bond, amino acid residue, etc.; R 7 and R 8 are hydrogen, alkyl, etc.; R 9 is hydrogen, alkyl, etc., and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation systems disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的1,3,4-噁二唑啉衍生物，其中W为氧、硫；R为氢、烷基、环烷A等；AA1为单键、氨基酸残基等；AA2为单键、氨基酸残基等；R7和R8为氢、烷基等；R9为氢、烷基等，以及其非毒性盐。 公式（I）的化合物对半胱氨酸蛋白酶具有抑制活性，因此可用作预防和/或治疗炎症性疾病、凋亡诱导的疾病、免疫反应紊乱引起的疾病、自身免疫疾病、由组成生物体的蛋白质分解引起的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌亢进等方面具有用途。
• PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Carter Percy H.

  公开号：US20070179148A1

  公开（公告）日：2007-08-02

  The present application describes modulators of MIP-1α of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R 1 , R 4 , R 5 , R 5a and R 5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

  本申请描述了式(I)的MIP-1α的调节剂，或其立体异构体或药学上可接受的盐，其中m、T、W、R1、R4、R5、R5a和R5b如本文所定义。此外，还公开了使用这些调节剂治疗和预防哮喘、过敏病等炎症性疾病，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理的方法。
• Metallaphotoredox-Catalyzed Cross-Electrophile C_sp³–C_sp³ Coupling of Aliphatic Bromides
  作者：Russell T. Smith、Xiaheng Zhang、Juan A. Rincón、Javier Agejas、Carlos Mateos、Mario Barberis、Susana García-Cerrada、Oscar de Frutos、David W. C. MacMillan

  DOI：10.1021/jacs.8b12025

  日期：2018.12.19

  pharmaceutically relevant aliphatic structures has been established via metallaphotoredox catalysis. Herein, we report that tris(trimethylsilyl)silanol can be employed as an effective halogen abstraction reagent that, in combination with photoredox and nickel catalysis, allows a generic approach to Csp3-Csp3 cross-electrophile coupling. In this study, we demonstrate that a variety of aliphatic drug-like groups

  已经通过金属光氧化还原催化建立了将小烷基片段安装到药学相关脂肪族结构上的策略。在此，我们报告了三（三甲基甲硅烷基）硅烷醇可用作有效的卤素提取试剂，与光氧化还原和镍催化相结合，可实现 Csp3-Csp3 交叉亲电偶联的通用方法。在这项研究中，我们证明了各种脂肪族类药物基团可以与许多市售的小烷基亲电试剂成功偶联，包括甲苯磺酸甲酯和应变环烷基溴。此外，两个二级脂肪族碳中心的结合是有机分子构建的长期挑战，已通过多种结构形式实现。最后的，
• Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
  申请人：——

  公开号：US20030166573A1

  公开（公告）日：2003-09-04

  An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1 wherein R is hydrogen, alkyl, CycA, etc.; AA 1 is a single bond, amino acid residue, etc.; AA 2 is a single bond, amino acid residue, etc.; R 7 and R 8 are hydrogen, alkyl, etc.; R 9 is hydrogen, alkyl, etc.; R 10 is hydrogen, alkyl, etc.). The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation system disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的一种噁二唑衍生物及其非毒性盐，其中R为氢、烷基、环烷A等；AA1为单键、氨基酸残基等；AA2为单键、氨基酸残基等；R7和R8为氢、烷基等；R9为氢、烷基等；R10为氢、烷基等。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，因此它可用作预防和/或治疗炎症性疾病、细胞凋亡诱导的疾病、免疫反应紊乱诱导的疾病、自身免疫疾病、由组成生物体的蛋白质分解诱导的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌虚弱等方面的药物。

表征谱图